e-learning
resources
Vienna 2003
Tuesday 30.09.2003
The challenge of community acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antibiotic therapy of
Pneumococcal
pneumonia with levofloxacin-a meta-analysis of 4 studies
G. Peiffer, P. Leophonte, J. P. Bru, P. Veyssier (Metz, Toulouse, Annecy, Compiegne, France)
Source:
Annual Congress 2003 - The challenge of community acquired pneumonia
Session:
The challenge of community acquired pneumonia
Session type:
Poster Discussion
Number:
3405
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Peiffer, P. Leophonte, J. P. Bru, P. Veyssier (Metz, Toulouse, Annecy, Compiegne, France). Antibiotic therapy of
Pneumococcal
pneumonia with levofloxacin-a meta-analysis of 4 studies. Eur Respir J 2003; 22: Suppl. 45, 3405
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP)
Source: Eur Respir J 2005; 26: Suppl. 49, 639s
Year: 2005
Effect of de-escalation antibiotic therapy on hospital-acquired, ventilator associated, and healthcare-associated pneumonia: A systematic review and meta-analysis
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016
Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin
Source: Eur Respir J 2003; 22: Suppl. 45, 543s
Year: 2003
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia
Source: Eur Respir J 2007; 30: 517-524
Year: 2007
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Year: 2017
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Impact of initial antibiotic choice on mortality from pneumococcal pneumonia
Source: Eur Respir J 2006; 27: 1010-1019
Year: 2006
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept